Start up. Grow up. Succeed.

BioNTech AG Receives Emerging Star of the Year Award at the European Mediscience Awards

BioNTech AG, a fully integrated biotechnology company developing individualized cancer immunotherapies is pleased to announce that it was presented with the “Emerging Star of the Year Award” at the European Mediscience Awards 2016.

Mainz, Germany 14th June 2016 - Sean Marett, Chief Operating Officer of BioNTech AG said: "We are proud to receive the Emerging Star Award, which is a tremendous honor for us. In the past year BioNTech has expanded rapidly and made significant progress publishing two groundbreaking scientific papers in Nature on personalized mRNA cancer vaccines, advancing its clinical immuno-oncology pipeline, with now four products in the clinic (and two more entering this year), expanding its GMP manufacturing, signing four collaborations with international pharmaceutical companies and launching its first molecular cancer diagnostic test internationally. BioNTech's progress supports its long term strategy of bringing its own pharmaceutical products to market. "

The Mediscience awards are the largest annual gathering of private and publicly quoted healthcare, biotech and life science companies in Europe. The event brings together the best of European Life Sciences companies to celebrate achievement and recognise success. Each year sees attendance of over 500 quoted and private European life science companies and their corporate advisors, analysts, fund manager, commentators and peers.

For more information, please contact:

BioNTech AG Hume Brophy

Regina Jehle
Tel: +49 (0) 6131 9084 1273

Hume Brophy
Mary Clark, Eva Haas, Hollie Vile
Tel: +44 (0) 20 7862 6381

About BioNTech AG:
BioNTech AG is an immunotherapy leader with bench-to-market capabilities, developing truly personalized, well-tolerated and potent treatments for cancer and other diseases. Established by clinicians and scientists the Group is pioneering disruptive technologies ranging from individualized mRNA based medicines through innovative Chimeric Antigen Receptors /T-cell Receptor-based products and novel antibody checkpoint immunomodulators. BioNTech's clinical programs are supported by an in-house molecular diagnostics unit whose products include MammaTyper® a molecular in-vitro diagnostic kit, marketed under CE and IVD marking in Europe and certain other countries. Founded in 2008, BioNTech is privately held and shareholders include the MIG Fonds, Salvia, and the Strüngmann Family Office, with the Strüngmann Family Office as the majority shareholder.
Information about BioNTech is available at